全文获取类型
收费全文 | 621篇 |
免费 | 39篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 7篇 |
妇产科学 | 7篇 |
基础医学 | 124篇 |
口腔科学 | 14篇 |
临床医学 | 44篇 |
内科学 | 132篇 |
皮肤病学 | 9篇 |
神经病学 | 73篇 |
特种医学 | 14篇 |
外科学 | 68篇 |
综合类 | 2篇 |
预防医学 | 43篇 |
眼科学 | 7篇 |
药学 | 10篇 |
肿瘤学 | 101篇 |
出版年
2023年 | 3篇 |
2022年 | 4篇 |
2021年 | 13篇 |
2020年 | 4篇 |
2019年 | 8篇 |
2018年 | 15篇 |
2017年 | 7篇 |
2016年 | 14篇 |
2015年 | 17篇 |
2014年 | 24篇 |
2013年 | 25篇 |
2012年 | 46篇 |
2011年 | 42篇 |
2010年 | 29篇 |
2009年 | 20篇 |
2008年 | 30篇 |
2007年 | 43篇 |
2006年 | 37篇 |
2005年 | 39篇 |
2004年 | 37篇 |
2003年 | 35篇 |
2002年 | 31篇 |
2001年 | 24篇 |
2000年 | 30篇 |
1999年 | 21篇 |
1998年 | 8篇 |
1997年 | 3篇 |
1995年 | 1篇 |
1994年 | 2篇 |
1993年 | 1篇 |
1992年 | 5篇 |
1991年 | 3篇 |
1990年 | 5篇 |
1989年 | 3篇 |
1988年 | 4篇 |
1987年 | 2篇 |
1986年 | 5篇 |
1985年 | 9篇 |
1984年 | 2篇 |
1983年 | 2篇 |
1982年 | 2篇 |
1980年 | 1篇 |
1979年 | 4篇 |
1974年 | 1篇 |
排序方式: 共有661条查询结果,搜索用时 0 毫秒
21.
22.
23.
Manola Zago Katharina Oehrlein Corinna Rendl Corinna Hahn-Ast Lothar Kanz Katja Weisel 《Annals of hematology》2014,93(12):1993-1999
Lenalidomide in combination with dexamethasone is an effective and well-established treatment of relapsed or refractory multiple myeloma (rrMM) disease. Due to the scarcity of reports assessing benefit and risk of long-term lenalidomide treatment in non-selected rrMM patients, we retrospectively analysed the long-term outcome in patients with rrMM treated with lenalidomide and dexamethasone. Sixty-seven patients (pts) who were treated with lenalidomide/dexamethasone for rrMM in the approved indication from 2007 to 2011 were included in this retrospective, single-centre analysis. Kaplan-Meier survival estimates were compared between total population, patients on lenalidomide for more than 12 months (mo) and patients discontinuing therapy earlier than 12 months. Median overall survival (OS) of the total patient population was 33.2 mo. OS of pts treated beyond 12 mo was 42.9 mo compared to 20.2 mo (p?=?0.027) for pts stopping lenalidomide earlier than 12 mo for other reasons than progression disease (PD). OS of pts >12 mo on lenalidomide treatment did not significantly differ between pts who had received previous autologous transplantation, allogeneic transplantation or conventional therapy. Main non-hematologic toxicities were infections of grade 3/4 in 25 % and thrombembolic events of all grades in 18 % of patients. To the best of our knowledge, this is the first report on feasibility and efficacy of long-term lenalidomide treatment in a non-selected patient cohort. OS of pts >12 mo on lenalidomide is superior when compared to pts discontinued earlier for reasons other than PD. Our data confirm the current use of lenalidomide as a continuous long-term treatment strategy. 相似文献
24.
Beta defensin‐1 gene polymorphisms and susceptibility to Atypical Squamous Cells of Undetermined Significance lesions in Italian gynecological patients 下载免费PDF全文
25.
26.
27.
Stefano Di Bella Giuseppina Campisciano Roberto Luzzati Enea Gino Di Domenico Antonio Lovecchio Aniello Pappalardo Manola Comar Giuseppe Gatti 《Interactive Cardiovascular and Thoracic Surgery》2021,32(3):457
Bacterial colonization has been already demonstrated in heart valve tissues of patients without cardiovascular infections. However, the evidence of a valvular microbiome is still scarce. The next-generation sequencing method was carried out on 34 specimens of aortic (n = 20) and mitral valves (n = 14) explanted from 34 patients having neither evidence nor history of infectious diseases, particularly infective endocarditis. While no bacteria were demonstrated using standard culture methods, bacterial deoxyribonucleic acid (DNA) sequences were found using next-generation sequencing in 15/34 (44%) cases. Escherichia coli was present in 6 specimens and was the most frequently identified bacterium. There was a trend towards a higher rate of bacterial DNA positivity in specimens of calcific valves than in those of non-calcific valves (10/17 vs 5/17, P = 0.17). Based on a quantitative test, E. coli accounted for 0.7% ± 1% in calcific valvular tissue and 0.3% ± 0.3% in non-calcific valvular tissue (P = 0.2), and for 11% ± 27% in the valvular tissue of diabetic patients and 0.3% ± 1% in the valvular tissue of non-diabetic patients (P = 0.08). Detection of bacterial DNA in non-endocarditis valvular tissues could be a relatively common finding. There could be an association between the valvular microbiome and certain models of valve degeneration and common metabolic disorders. 相似文献
28.
Paulo César Simamoto‐Júnior DDS MS PhD Alfredo Júlio Fernandes‐Neto DDS MS PhD Flávio Domingues Neves DDS MS PhD Talita Souza Dantas DDS MS Lucas Zago Naves DDS MS PhD 《Journal of prosthodontics》2015,24(2):168-171
In the event of the loss of an implant and to take advantage of the preexisting structures, a rescue procedure that allows continuous use of the original fixed restoration during the restoration of the tripod support at the implant level can be used. When nonphysiological occlusion forces are avoided, the success rate of this rescue procedure is very similar to any other rehabilitation made following a conventional protocol. Furthermore, the fact that the patient has already adapted to the prosthesis position and its vertical dimension results in easier functional adaptation in the postoperative period and, consequently, greater comfort. 相似文献
29.
First‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody,in healthy volunteers 下载免费PDF全文
Martin Koller MD MPH Daniel K. Ness DVM PhD Sue G. Griffith MD PhD MRCP Michael Grundman MD MPH Wagner Zago PhD Jay Soto BS George Atiee MD Susanne Ostrowitzki MD PhD Gene G. Kinney PhD 《Movement disorders》2017,32(2):211-218
Background : α‐Synuclein is a major component of pathologic inclusions that characterize Parkinson's disease. PRX002 is an antibody that targets α‐synuclein, and its murine parent antibody 9E4 has been shown in preclinical studies to reduce α‐synuclein pathology and to protect against cognitive and motor deteriorations and progressive neurodegeneration in human α‐synuclein transgenic mice. Methods : This first‐in‐human, randomized, double‐blind, placebo‐controlled, phase 1 study assessed the impact of PRX002 administered to 40 healthy participants in 5 ascending‐dose cohorts (n = 8/cohort) in which participants were randomly assigned to receive a single intravenous infusion of study drug (0.3, 1, 3, 10, or 30 mg/kg; n = 6/cohort) or placebo (n = 2/cohort). Results : PRX002 demonstrated favorable safety, tolerability, and pharmacokinetic profiles at all doses tested, with no immunogenicity. No serious adverse events, discontinuations as a result of adverse events, or dose‐limiting toxicities were reported. Serum PRX002 exposure was dose proportional; the average terminal half‐life across all doses was 18.2 days. A significant dose‐dependent reduction in free serum α‐synuclein (unbound to PRX002) was apparent within 1 hour after PRX002 administration, whereas total α‐synuclein (free plus bound) increased dose‐dependently, presumably because of the expected change in kinetics following antibody binding. Conclusions : This study demonstrates that serum α‐synuclein can be safely modulated in a dose‐dependent manner after single intravenous infusions of an anti–α‐synuclein antibody. These findings support continued development of PRX002, including further characterization of its safety, tolerability, pharmacokinetics, and pharmacodynamic effects in the central nervous system in patients with Parkinson's disease. © 2016 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society. 相似文献
30.
Rafaela Azevedo Abrantes de Oliveira RN Vander Monteiro da Conceição RN Jeferson Santos Araujo RN Márcia Maria Fontão Zago RN 《International journal of nursing practice》2018,24(1)